Zaineb Nadeem

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial”.

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

Nature Medicine(2023)10.1038/s41591-023-02518-x

N/A

1.3DataRank · unranked

58 citations

Bharat Burman, Swati Jain, Conall Fitzgerald, Eric J. Sherman, Lara Dunn +24 more

The association between tumor mutational burden and prognosis is dependent on treatment context

Nature Genetics(2021)10.1038/s41588-020-00752-4

N/A

0DataRank · unranked

262 citations

Mark Lee, Douglas R. Hoen, Jingming Wang, Zaineb Nadeem, Neal Patel +22 more

Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy

Molecular Cancer Research(2021)10.1158/1541-7786.mcr-21-0442

N/A

0DataRank · unranked

20 citations

Brian R. Untch, Bin Xu, Ronald Ghossein, Catherine Han, Fengshen Kuo +12 more

The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3758

N/A

0DataRank · unranked

126 citations

Fengshen Kuo, Nora Katabi, Mark Lee, Zaineb Nadeem, Martin G. Dalin +11 more

Data from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype

(2023)10.1158/1078-0432.c.6529017.v1

N/A

0DataRank · unranked

0 citations

Fengshen Kuo, Nora Katabi, Mark Lee, Zaineb Nadeem, Martin G. Dalin +11 more

Data from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy

(2023)10.1158/1541-7786.c.6545222.v1

N/A

0DataRank · unranked

0 citations

Brian R. Untch, Bin Xu, Ronald Ghossein, Catherine Y. Han, Fengshen Kuo +12 more

Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1064

N/A

0DataRank · unranked

7 citations

Joris L. Vos, Nora Katabi, Fengshen Kuo, Zaineb Nadeem, Maximilian Linxweiler +8 more